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Introduction
Accumulation of amyloid-β (Aβ) in the brain is a key event in Alz-
heimer’s disease (AD) pathogenesis. Recent evidence suggests 
that in the common sporadic or late-onset forms of AD and in 
some cases of familiar AD (FAD) elevated Aβ brain levels result 
from impaired clearance instead of overproduction (1). The most 
prominent variants of Aβ consist of the first 40 (Aβ1–40) and 42 
(Aβ1–42) amino acids, respectively. The two additional hydropho-
bic amino acids of Aβ1–42 generate a more aggregation-prone and 
neurotoxic peptide (2). Low Aβ levels within the healthy brain are 
maintained through degradation, elimination via interstitial fluid 
(ISF) bulk flow, cerebrospinal fluid (CSF) absorption into the cir-
culatory and lymphatic system, or transport across the blood-brain 
barrier (BBB) (3, 4). Cell-surface receptor low-density lipoprotein 
receptor–related protein-1 (LRP1) has been reported to be involved 
not only in Aβ endocytosis and cerebral degradation (5–7), but also 
in Aβ transcytosis through the brain endothelium and subsequent 
systemic elimination via liver, spleen, and kidneys (8).
Aging is the most prominent risk factor for AD. LRP1 expres-
sion decreases in total brain and brain capillaries with age (8, 9). 
Moreover, LRP1 is further reduced in AD (8, 10). Additionally, 
highly validated genetic risk factors for AD, like the apolipoprotein 
E (apoE) Ε4 allele or the gene encoding the phosphatidylinosi-
tol-binding clathrin assembly (PICALM), are believed to be linked 
to reduced clearance of Aβ via LRP1 (11–13). In senile plaques, 
LRP1 ligands, like apoE, urokinase-type plasminogen activator, 
tissue plasminogen activator, and lactoferrin, co-deposit with Aβ, 
all together indicating a loss of LRP1 function in AD (14). Recent 
studies suggest that transport across the BBB is a major elimi-
nation route for brain Aβ (8, 11, 12, 15). Thus, the neurovascular 
hypothesis of AD states that Aβ accumulation is driven by impair-
ment of Aβ transporters in brain capillaries, resulting in deficient 
Aβ elimination via the BBB (3, 8, 15, 16).
However, there are conflicting studies showing no or little con-
tribution of LRP1 to Aβ clearance across the BBB (5, 17–20). Due 
to the lack of appropriate model systems, the role of LRP1 at the 
BBB and the overall relevance of BBB clearance are insufficiently 
understood and debated (4, 7). Many Aβ clearance studies make 
use of LRP1 inhibition through injected antibodies or low-density 
lipoprotein receptor (LDLR) family antagonists; however, this 
approach does not allow the specific inhibition of the BBB clear-
ance pathway (21). Global Lrp1 knockout mice are embryonically 
lethal (22, 23). Until now, no animal model had been available 
to study the role of LRP1 at the BBB. Using a brain endothelial–
specific Cre-expressing mouse line (24), we generated what we 
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in both groups of mice (Figure 3C). CD11b-positive cells away 
from vessel-shaped structures in both groups of mice showed 
little colocalization, consistent with previous findings showing 
weak expression of LRP1 in some glial cells only (27, 29–31). 
Primary microglia, neurons, and astrocytes isolated from adult 
Lrp1BE–/– mice showed abundant LRP1 expression after tamoxifen 
induction (Supplemental Figure 4). We could not see any effects 
on the in vivo BBB permeability due to the knockout of Lrp1 in 
endothelial cells. Brain permeability for IgG and the low-mo-
lecular-weight marker Na-fluorescein did not show differences 
between genotypes, indicating an intact BBB in vivo (Figure 4).
Deletion of Lrp1 in brain endothelium results in reduced [125I] 
Aβ1–42 transcytosis in vitro. Previously, we have shown that pri-
mary brain endothelial cells with inactive LRP1 harboring an 
NPxYxxL mutation in the endocytosis motif transcytosed signifi-
cantly less Aβ than WT cells (32). Moreover, several in vivo stud-
ies have suggested that LRP1 is involved in Aβ clearance across 
the BBB (8, 11, 12, 15, 21, 33). However, other studies have failed 
to see a LRP1 contribution to Aβ BBB clearance in various mod-
els (5, 17–19). To understand the discrepancies between previ-
ous works, we studied Aβ transport across a Lrp1-deficient brain 
endothelial monolayer in a standard model (5, 32, 34). In the 
presence of the paracellular marker [14C]-inulin, we investigated 
[125I] Aβ1–42 transport at physiologically relevant concentrations 
(0.1 nM). The aggregation-prone Aβ1–42 variant is the major pep-
tide found in senile plaques and is thought to be a driving agent 
in AD pathology (2). After 45 minutes, we observed that signifi-
cant amounts of TCA-precipitable radioactivity, representing 
intact peptide, were transported across the endothelial mono-
layer. Moreover, brain endothelial cells lacking LRP1 transcy-
tosed approximately 50% less [125I] Aβ1–42 than brain endothelial 
cells isolated from littermate controls harboring the Lrp1 allele 
(Figure 5A). Then, we investigated a range of different physio-
logically relevant Aβ concentrations to validate our findings. We 
used Aβ concentrations ranging from 0.05 nM, normally found 
in plasma of healthy individuals (15), to 5 nM, corresponding to 
elevated Aβ levels in brains of patients with AD and AD animal 
models (15). At all concentrations studied, we could verify our 
previous findings, showing that Lrp1 knockout endothelial cells 
transcytosed significantly less [125I] Aβ1–42 than control endothe-
lial cells (Figure 5B). Interestingly, we observed the increasing 
contribution of LRP1 in receptor-mediated transcytosis of [125I] 
Aβ1–42 at rising Aβ concentrations. This demonstrated that LRP1, 
with an extremely fast endocytosis rate (35), has a major function 
as an Aβ clearance receptor in endothelial cells.
Deletion of Lrp1 in brain endothelium impairs Aβ efflux from 
brain. After verification of LRP1-mediated Aβ transcytosis, we 
aimed to study the role of endothelial LRP1 in vivo with the 
brain efflux index method (8, 11, 12, 15). It has been shown that 
clearance rates for [125I]-labeled Aβ and unlabeled Aβ are virtu-
ally identical (11). Therefore, pathophysiological concentrations 
of [125I]-radiolabeled, monomeric Aβ1–42 (5.14 nM) were injected 
simultaneously with 40 μCi/ml [14C]-inulin into ISF of Lrp1BEfl/fl 
and Lrp1BE–/– littermates. [14C]-inulin is not actively cleared or 
retained in the brain and acts as a reference marker of ISF bulk 
flow. We injected [14C]-inulin and [125I]Aβ1–42 into the caudate 
putamen, distant from the ventricular system, to promote BBB 
believe to be a novel Lrp1 knockout model. We show that selective 
deletion of Lrp1 in brain capillaries strongly reduces Aβ efflux from 
brain. Using physiological Aβ concentrations, we demonstrate that 
major amounts of injected radiolabeled Aβ are cleared via endo-
thelial LRP1 across the BBB. In an AD mouse model, deletion 
of brain endothelial Lrp1 results in reduced plasma Aβ, elevated 
soluble brain Aβ, and deficits in spatial memory, underlining the 
importance of systemic Aβ elimination via the BBB.
Results
Slco1c1-CreERT2 × Lrp1fl/fl mice fully excise Lrp1 specifically in brain 
endothelium. To investigate the function of brain endothelial LRP1, 
we bred Lrp1fl/fl mice (25) with tamoxifen-inducible Slco1c1-CreERT2 
mice, producing Lrp1BEfl/fl mice (24). Upon induction, Slco1c1-
CreERT2 mice have been shown to express Cre recombinase exclu-
sively in brain endothelial cells and choroid plexus epithelial cells 
but not in other vascular territories. Apart from little recombina-
tion in 7% of astrocytes, hardly any Cre is expressed in other cell 
types of the brain or peripheral organs (24).
Tamoxifen injection in WT mice did not affect Lrp1 expres-
sion (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI81108DS1). Tamoxifen 
injection into Lrp1BEfl/fl mice carrying the Cre allele resulted in a 
full Lrp1 knockout in brain endothelium (herein referred to as 
Lrp1BE–/–), as shown in immunohistochemical staining of corti-
cal brain sections with monoclonal anti-LRP1 11E2 (Figure 1A 
and Supplemental Figures 2 and 3). Likewise, analysis of lysates 
revealed the absence of the protein in brain endothelial cells of 
Lrp1BE–/– mice (Figure 1B). Full Lrp1 deletion was also confirmed 
via PCR analysis (26) on the genomic level (Figure 1C). Having 
shown full deletion of Lrp1 in brain endothelium of Lrp1BE–/– mice, 
we wanted to verify brain endothelial–specific Cre activity, as 
reported for Slco1c1-CreERT2 mice (24). A closer look at the vascu-
lature revealed that CD31-negative cells adjacent to the endothe-
lium that make up the neurovascular unit were positive for LRP1 
in Lrp1BE–/– mice (Figure 1A and Supplemental Figure 3), showing 
brain endothelial–specific expression of Cre recombinase and no 
leakage of Cre recombinase in surrounding cells. In both groups, 
cells surrounding the vasculature showed widespread expression 
of LRP1. Ubiquitous expression for LRP1 throughout the brain 
has been reported previously (27). Next, we determined LRP1 
abundance in capillary-depleted brain fractions of Lrp1BE–/– and 
Lrp1BEfl/fl mice with different LRP1 antibodies. Neither with the 
monoclonal N-terminal 11E2 (Supplemental Figure 2) nor with 
the well-described polyclonal C-terminal antibody 1704 could 
we see differences in Lrp1 expression in brain tissue deprived of 
capillaries (Figure 2). Moreover, we detected LRP1 and differ-
ent cell markers in cortical brain sections of these mice. NeuN- 
positive neurons showed strong LRP1 expression in the soma 
of neurons (Figure 3A), validating high LRP1 expression in neu-
ronal cell bodies as reported previously (28, 29). In addition, the 
vast majority of glial fibrillary acidic protein–positive (GFAP- 
positive) astrocytes in Lrp1BE–/– mice were LRP1 positive (Fig-
ure 3B). Little recombination in 7% of astrocytes for this mouse 
line has been reported before (24). With anti-LRP1 11E2 and a 
marker for microglia and macrophages (anti-CD11b), we showed 
costaining of LRP1 and CD11b around vessel-shaped structures 
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BBB to Aβ clearance contribu-
tion in Lrp1BE–/– and Lrp1BEfl/fl 
mice. We detected that rapid 
BBB transport was reduced 
by about 48% in Lrp1BE–/– mice 
(Figure 6C), whereas clear-
ance through slow ISF bulk 
flow, a minor component of 
Aβ brain efflux (8), was not 
altered (Figure 6B). By sub-
tracting BBB-mediated clear-
ances of Lrp1BE–/– animals from 
Lrp1BEfl/fl animals, we calculated 
the amount of Aβ clearance 
mediated by brain vasculature 
LRP1. We found that at 5.14 nM 
[125I] Aβ1–42, 47.5% of Aβ1–42 BBB 
clearance was mediated by 
brain endothelial LRP1. There-
fore, brain endothelial LRP1-
mediated clearance accounted 
for approximately 27% of total 
Aβ1–42 clearance (Figure 6F) at 
the Aβ concentration used in 
the study. As Lrp1 excision is 
restricted to the brain endo-
thelium, clearance by brain 
vasculature LRP1 could also 
be determined by subtracting 
total clearance in Lrp1BE–/– mice 
from total clearance in Lrp1BEfl/fl 
mice. Both calculations revealed 
that, at pathophysiological con-
centrations, about 27% of total 
Aβ1–42 clearance is mediated by 
LRP1 in the brain endothelium, 
demonstrating the importance 
of systemic clearance across 
the BBB. In order to clear about 70% of injected [125I] Aβ1–42, mice 
lacking Lrp1 in brain endothelium needed about 4 times longer 
than control mice (Figure 6A, 60 minutes for Lrp1BE–/– versus 
15 minutes for Lrp1BEfl/fl), stressing the importance of endothe-
lial LRP1 in rapid Aβ clearance. Interestingly, 30 minutes after 
CNS injection, Aβ brain retention in both groups approximated a 
respective plateau, with reduction (about 44%) of Aβ brain reten-
tion in brains of Lrp1BEfl/fl animals, even 3 hours after injection of 
these small amounts of tracers (Figure 6A). This suggested that 
approximately 44% of the low nM Aβ pool in mice still present 
after 3 hours could only be cleared when LRP1 was present in 
brain endothelium.
To investigate the importance of LRP1 on BBB Aβ clearance 
in a well-established mouse AD model, we crossed the Lrp1BEfl/fl 
mice with 5xFAD mice. These mice express 5 FAD mutations 
under Thy-1 promotor control to increase overall Aβ1–42 produc-
tion in the brain (37). Through deletion of brain endothelial Lrp1 
in 5xFAD mice we could study Aβ transport without the need to 
inject radiolabeled peptides.
clearance across capillaries instead of CSF-blood barrier clear-
ance across the choroid plexus. First, we determined the time 
frame for linear [125I] Aβ efflux, since low concentrations of [125I] 
Aβ are rapidly cleared (36). Precipitating brain radioactivity 
at designated time points after Aβ injection, we observed that 
at each time point Lrp1BE–/– mice retained more [125I] Aβ1–42 than 
Lrp1BEfl/fl mice (Figure 6A). Within the first 20 minutes, Aβ was 
cleared in a linear manner, with 47.7% more clearance in Lrp1BEfl/fl 
mice studied 15 minutes after injection (Figure 6A). The paracellular 
marker [14C]-inulin was cleared in a slow, passive, and equal man-
ner in both groups, demonstrating an intact BBB (Figure 6B). 
Importantly, both tracers were hardly detectable in CSF, with no 
differences among the groups (Figure 6, D and E). This impli-
cated that the low concentrations of Aβ injected into the caudate 
putamen were mostly eliminated by rapid clearance across the 
microvessels and not by clearance from the ISF into the CSF. The 
amounts of tracers found in the plasma were low due to rapid 
systemic body clearance (8). As 15 minutes after microinjection 
[125I] Aβ efflux was linear, we calculated the contribution of the 
Figure 1. Full deletion of Lrp1 in Lrp1BE–/– mice. (A) Immunofluorescent staining for endothelial marker CD31 and 
LRP1 in cortical brain sections demonstrated complete knockout of Lrp1 in brain endothelium of Lrp1BE
–/– animals, 
while Lrp1 expression in surrounding cells remained unaffected (white arrows). DRAQ5 was used to stain cell 
nuclei. Scale bar: 20 μm. (B) Immunostaining in isolated endothelial cells showed knockout of Lrp1 in Lrp1BE–/– mice. 
Primary cortical endothelial cell and control lysates of LRP1-expressing CHO cells (K1) and LRP1 knockout (13-5-1) 
cells were analyzed on the same Western blot but rearranged for clearer presentation. An anti–β-actin immunoblot 
is shown as a loading control. (C) PCR analysis revealed complete Cre-mediated excision of the loxP-flanked Lrp1 
allele in brain endothelium. Endothelial genomic DNA was used for PCR detecting the WT (WT/WT, 507 bp), the 
loxP-flanked (fl/fl, 541 bp), and the excised allele (–/–, 325 bp) simultaneously in one reaction. Data show repre-
sentative results from experiments performed in triplicate.
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brain endothelial LRP1 medi-
ated approximately 50% of 
Aβ1–42 transport across the BBB 
in vivo and in vitro, we analyzed 
Aβ1–42/Aβ1–40 ratios in brains and 
plasma of 5xFAD Lrp1BE–/– mice 
and littermate controls. 5xFAD 
mice showed a preferential 
generation of Aβ1–42 over Aβ1–40 
due to the mutations in amy-
loid precursor protein (APP) and 
presenilin-1 (37). In 7-month-old 
5xFAD Lrp1BEfl/fl animals, both 
soluble and insoluble Aβ1–42/Aβ1–
40 brain ratios were significantly 
elevated (Figure 9), suggesting 
that LRP1 preferentially clears 
Aβ1–40, even when Aβ1–42 is of 
higher abundance. Additionally, 
the plasma Aβ1–42/Aβ1–40 ratios 
in 5xFAD Lrp1BEfl/fl animals were 
lowered by about the same fold (Figure 9). This demonstrates 
that LRP1 preferentially binds Aβ1–40 when available, confirming 
previous findings showing a differential affinity of LRP1 to the 
two Aβ variants (15).
Brain endothelial LRP1 deficiency exacerbates Aβ-dependent 
cognitive deficits. Next, we investigated how brain endothelial 
LRP1 deficiency affects AD-related behavior by examining spa-
tial learning and memory (40, 41). We used three different tests 
to examine motor deficits, string suspension, inverted grip, 
and balance beam, and found that no mice in any tested group 
showed abnormalities (Supplemental Figure 6). The ability of 
vision of the mice was tested by visual placing (42) before mice 
entered the Morris water maze. The Morris water maze is a par-
ticularly sensitive test to examine age-related memory impair-
ments in AD mice. Previously, it has been shown that 5xFAD 
mice display AD-like memory deficits at 12 months of age (43). 
Same-aged WT mice, however, did not show these deficits. As 
we saw that knockout of Lrp1 in the brain cerebrovasculature of 
5xFAD mice severely elevated the soluble brain Aβ levels, we 
investigated whether 5xFAD Lrp1BEfl/fl mice displayed memory 
deficits early and examined spatial learning and memory at 7 
months of age. Spatial learning tests in 5xFAD Lrp1BE–/– mice 
after acquisition training showed significantly higher escape 
latencies on days 3, 4, and 5 compared with those of the rest 
of the groups (Figure 10A). Swimming speeds did not differ 
among groups (Figure 10B). These results suggest that spatial 
learning is impaired in 5xFAD Lrp1BE–/– mice. The probe trial 
for monitoring spatial reference memory revealed that 3 of 4 
groups, including 5xFAD Lrp1BEfl/fl mice, displayed a significant 
preference for the target quadrant, whereas no quadrant pref-
erence was found for 5xFAD Lrp1BE–/– mice (Figure 10, C and D). 
Swimming speeds did not differ among groups (Figure 10E). In 
summary, the results illustrated that endothelial-specific Lrp1 
knockout in 5xFAD mice and, therefore, reduced clearance of 
Aβ peptides induced an impairment of both spatial learning and 
spatial reference memory.
We determined Aβ efflux and brain retention in 7-month-
old 5xFAD Lrp1BEfl/fl and 5xFAD Lrp1BE–/– mice. 5xFAD Lrp1BE–/– 
mice showed reduced plasma levels of both Aβ1–40 and Aβ1–42 
associated with reduced Aβ transport out of the brain (Figure 
7, A, D, and E). In line with these data, we found significantly 
higher levels of soluble Aβ in 5xFAD Lrp1BE–/– brains, consis-
tent with impaired transport of Aβ out of the brain (Figure 
7, B, F, and G). Soluble Aβ levels were elevated about 2.5-fold 
for Aβ1–42 and about 3.7-fold for Aβ1–40 in 5xFAD Lrp1BE–/– mice. 
Insoluble Aβ1–42 levels showed a trend toward higher levels in 
5xFAD Lrp1BE–/– mice, with higher variations in individual mice 
(Figure 7, C, H, and I). Therefore, we determined the absolute 
Aβ levels in 5xFAD Lrp1BE–/– mice and littermates via ELISA. 
Reflecting the immunoprecipitation data, 7-month-old 5xFAD 
mice had significantly higher soluble Aβ levels (approximately 
4.8-fold for Aβx–40 and 3.1-fold for Aβx–42) and insoluble Aβx–40 
levels (approximately 2.0-fold change) when LRP1 was absent in 
brain endothelium (Figure 7, L and M). Again, there was a trend 
toward higher insoluble Aβx–42 levels that did not reach statisti-
cal significance (Figure 7L). Plaque load quantification mirrored 
the data collected from prior measurements and showed no 
significant difference in plaque load in the hippocampus (Fig-
ure 7, J and K), cortex, or subiculum (Supplemental Figure 5). In 
AD, activated astrocytes and microglia play an important role 
in clearing Aβ deposits by triggering phagocytic uptake (38, 39). 
Both AD models showed reactive astrocytes and microglia in 
the hippocampus (Figure 8). However, we found no significant 
difference in Iba1 or GFAP immunoreactivity between 5xFAD 
Lrp1BE–/– and 5xFAD Lrp1BEfl/fl mice.
All together, the collected data from two different in vivo 
models indicated that brain endothelial LRP1 substantially 
regulates the soluble brain Aβ levels and that LRP1-mediated 
transport across the BBB is a major pathway of Aβ clearance.
Differential binding affinity of LRP1 to Aβ1–40 and Aβ1–42 spe-
cies. There are several studies showing higher binding affinity 
of LRP1 to Aβ1–40 than to Aβ1–42 (11, 15). Since we observed that 
Figure 2. No difference in Lrp1 expression in capillary-depleted brain fractions of Lrp1BE–/– and Lrp1BEfl/fl 
mice. (A) Immunostaining of LRP1 α chain and β chain in brain fractions deprived of capillaries. An  
anti–β-actin immunoblot is shown as a loading control. MEF, mouse embryonic fibroblast. (B and C) Quan-
tification of relative abundance of (B) LRP1 α chain and (C) LRP1 β chain in brain fractions deprived of cap-
illaries. Data show representative results of 3 to 5 mice per group from experiments performed in triplicate 
(mean ± SEM). For statistical analyses, unpaired t test was used.
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Discussion
Epidemiological studies have shown that risk 
factors for vascular diseases, like diabetes mel-
litus, atherosclerosis, stroke, hypertension, and 
microvessel pathology, are closely associated with 
AD (3, 44, 45). Moreover, basically all risk factors for 
AD have vascular components that reduce cerebral 
perfusion, affecting brain clearance of toxins such 
as Aβ, providing further evidence for the impor-
tance of cerebrovasculature function in the healthy 
brain (2, 45). The knockdown of LRP1 in the endo-
thelium of zebrafish has resulted in reduced blood 
flow and demonstrated the importance of LRP1 in 
vasculogenesis (46). The neurovascular hypothesis 
suggests that impaired Aβ clearance by BBB trans-
porters leads to rising Aβ brain levels and the initi-
ation and progression of AD. Recently, it has been 
shown that genetic risk factors for AD are linked 
to reduced clearance of Aβ via LRP1 (12, 13). How-
ever, controversial findings from different groups 
and the lack of appropriate models to study BBB 
transporters have created growing ambiguity in the 
field (8, 11, 12, 15, 17–19, 47). Previous reports have 
shown no contribution for LRP1 to transcytosis of 
Aβ in different BBB models (5, 18, 19), and research 
teams have doubted that the expression of Lrp1 in 
brain endothelium is sufficient to mediate substan-
tial Aβ clearance (7, 28, 48, 49). Here, with the first 
brain endothelial–specific Lrp1 knockout model to 
our knowledge, we show that LRP1 in brain endo-
thelial cells is a key transporter mediating Aβ efflux 
out of the brain. Deletion of Lrp1 in brain endothe-
lium in an AD mouse model enhances Aβ accumu-
lation and leads to AD-related behavioral deficits.
To our knowledge, Cre recombinase under the 
control of endothelial cell–specific promoters has 
not been used to address the role of brain endothe-
lium in Aβ clearance. Previous studies have high-
lighted the importance of Aβ clearance by cellular 
degradation in neurons (6), astrocytes (39), micro-
glia cells (38), and vascular smooth muscle cells (7). 
Numerous studies have tried to show the relevance 
of BBB contribution to Aβ clearance in vivo; how-
ever, they have failed to specifically inhibit brain 
vasculature LRP1 or have neglected the role of Aβ 
degradation within the brain (8, 11, 15, 33). Here, for 
what we believe to be the first time, a BBB-specific 
knockout mouse was used to evaluate the relevance 
of Aβ BBB clearance via LRP1.
We studied whether clearance of AD pathol-
ogy–driving Aβ1–42 is affected in Lrp1BE–/– mice. Using 
physiological Aβ concentrations, we observed that 
half of the BBB clearance is mediated by brain 
endothelial LRP1 in various model systems. In 
vivo, plasma Aβ levels in 5xFAD mice were signifi-
cantly reduced and soluble brain levels were sig-
nificantly elevated when LRP1 was absent in brain 
Figure 3. Brain endothelial–specific deletion of Lrp1 in Lrp1BE–/– mice. Immunofluores-
cent staining in cortical brain sections for LRP1 and (A) NeuN-positive neuronal cells, 
(B) GFAP-positive astrocytes, and (C) CD11b-positive microglia and macrophages to 
determine potential recombination in macrophages/microglia, neurons, and astrocytes 
revealed no differences between genotypes. Scale bar: 20 μm. Data show representative 
results from experiments performed in triplicate.
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endothelium. When injecting low nM [125I] Aβ1–42 concentrations 
in mice, we found no significant amount of radioactivity in the 
CSF, showing that the small amounts of injected Aβ are rapidly 
cleared via the BBB and that a minor amount of injected Aβ is 
cleared via bulk flow as also observed by previous studies (8, 11, 
12). We found that approximately 48% of BBB transport is medi-
ated by LRP1. This is in line with previous studies showing that 
Aβ brain efflux can be reduced to approximately 50% by coin-
jecting LRP1 antibodies or antagonists (8, 21). Moreover, it has 
been shown that deletion of very LDLR (VDLDR) and LDLR 
genes did not significantly affect Aβ brain clearances, suggesting 
a minor importance of other LDL receptors in Aβ brain-to-blood 
transport (15). Besides, our data collected from the 180-minute 
time point suggest that brain endothelial LRP1 is able to clear 
low nM Aβ pools that can only be cleared by the LRP1. Having 
shown that LRP1 in brain endothelium in vivo mediates approx-
imately 27% of total Aβ clearance at pathophysiological levels, 
LRP1 at the BBB seems to be a key player in AD pathology. In 
addition, the in vitro transport studies revealed a 
substantial contribution of LRP1 in Aβ transcyto-
sis. The data furthermore suggest that, at elevated 
Aβ concentrations, like during the progression of 
AD, the importance of Aβ clearance by fast endo-
cytic receptor LRP1 is crucial. While, at picomolar 
concentrations, the contribution of LRP1-mediated 
clearance was 49.2% (0.1 nM Aβ), it increased with 
rising Aβ concentrations to 65.4% at 5 nM Aβ. This 
could be due to the high Aβ-binding capacity and 
the fast endocytosis rate of LRP1. It has been shown 
that, at 5 nM, Aβ binding to LRP1 is not yet saturated 
(50, 51). Moreover, with an endocytosis rate up to 
16 times faster than that of other Aβ receptors, such 
as VDLDR or LDLR (12, 35), LRP1 may outperform 
other receptors in Aβ clearance, especially at higher 
concentrations. Additionally, in the 5xFAD mouse 
model, we could collect in vivo data on the impor-
tance of LRP1 in clearance at higher Aβ levels. Aβ 
brain levels in 5xFAD mice rise with age (37). In 
7-month-old 5xFAD Lrp1BE–/– animals, the plasma 
levels for both Aβ1–40 and Aβ1–42 are 
strongly reduced and the brain levels 
highly elevated, each by more than 
50%. This strong effect is probably not 
solely the result of deficient BBB and 
CSF-blood clearance in these animals 
but could also be due to the predomi-
nant importance of LRP1 at rising Aβ 
levels in aging animals.
Previous studies have shown higher 
binding affinity of LRP1 to Aβ1–40 and 
faster clearance of this variant than 
of Aβ1–42 (11, 15). We confirmed these 
findings in 5xFAD Lrp1BE–/– mice in 
vivo. When measuring the Aβ1–42/Aβ1–40 
ratio in 5xFAD mice, we saw that both 
Aβ variants were cleared by LRP1 but 
noticed preferential clearance of Aβ1–40. 
This binding affinity difference could lead to fatal consequences in 
patients. When LRP1 expression decreases during aging and in AD 
(8, 10), fewer receptors will not only cause rising Aβ accumulation in 
the brain, but will preferentially clear less toxic Aβ1–40 and therefore 
cause a shift in the Aβ1–42/Aβ1–40 ratio, leading to higher concentra-
tions of aggregation-prone Aβ1–42. The binding affinity results, as 
well as the predominant importance of LRP1 at elevated Aβ concen-
trations, support the idea that maintaining steady Aβ clearance at 
the BBB by LRP1 could be a potential target for treatment of age- 
related neurological disorders (51).
We are aware that there are conflicting findings on LRP1 in 
previous studies. These results might be due to Aβ injections 
at concentrations beyond physiological relevance into differ-
ent brain regions (17, 18, 52) or the use of epithelial cells, such as 
MDCK and CHO cells (5, 19), for in vitro studies. Cell-specific 
functions of receptors have been reported for other members of 
the LDLR family (53), so the function of LRP1 might be dependent 
on cell type and polarization state, as suggested before (21, 32). 
Figure 4. Deletion of Lrp1 in Lrp1BE–/– mice does not affect BBB integrity. (A) Brain IgG extravasation 
and (B) fluorescein permeability studies in Lrp1BEfl/fl (n = 5) and Lrp1BE–/– (n = 8) mice showed no effect 
of Lrp1 knockout on BBB permeability in vivo. (A) Brain lysates were analyzed by Western blotting 
and normalized to β-actin. (B) Mice were injected with Na-fluorescein, and fluorescence intensity of 
brain homogenates (emission at 519 nm, excitation at 488 nm) was normalized to brain weight. Data 
represent mean ± SEM. For statistical analyses, unpaired t test was used.
Figure 5. LRP1 in brain endothelial cells substantially contributes to [125I] Aβ1–42 transcy-
tosis in vitro. [125I] Aβ1–42 transport across the primary mouse brain capillary endothelial 
cell monolayer was studied in the presence of 1 μCi/ml [14C]-inulin to determine the 
transcytosis quotient (TQ). Transcytosis was analyzed in the brain-to-blood direction 
(abluminal to luminal) by measuring the dpm for [14C]-inulin and the cpm for the TCA-
precipitable [125I] radioactivity. The TQ of Lrp1BE
–/– brain endothelial cells was normalized to 
Lrp1BE
fl/fl brain endothelial cells. (A) Transport at a physiological concentration of 0.1 nM Aβ 
(Lrp1BE
fl/fl, n = 18; Lrp1BE
–/–, n = 14; 4 independent experiments). (B) Higher contribution of 
LRP1 in transport of [125I] Aβ1–42 at higher Aβ concentrations (n = 6, n = 4, n = 5, n = 4, n = 3, 
n = 4, n = 3, n = 3 from left to right). Data represent mean ± SEM. For statistical analyses, 
unpaired t test was used. *P < 0.05, **P < 0.01, ***P < 0.001.
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Here, in the two BBB-specific knockout mouse models of Lrp1, we 
can positively say that the expression of LRP1 in brain endothelial 
cells strongly modulates soluble brain Aβ levels.
Aβ1–40 and Aβ1–42 are the prevalent Aβ species found in amy-
loid plaques. In 7-month-old 5xFAD mice, we could not detect 
any significant differences in plaque deposition or gliosis when 
impairing a major Aβ elimination pathway through brain endo-
thelial–specific deletion of Lrp1. However, absence of LRP1 in 
brain endothelium had striking effects on the concentrations of 
soluble Aβ species in the brain and resulted in significant cogni-
tive deficits. As recent works suggest, the concentrations of sol-
uble Aβ species, not the presence of plaques, seem to strongly 
correlate with the cognitive deficits in mouse models (54) and 
AD pathology in patients (55, 56). In their study with 19 patients 
with AD and 18 controls, McLean and colleagues discovered that 
insoluble Aβ in humans appeared only to signify the presence of 
AD and that soluble Aβ concentrations seemed to correlate with 
the severity of disease. Moreover, their data on patients with AD 
showed a higher proportion of Aβ1–42 in the soluble fractions, pos-
sibly representing an intracellular and more neurotoxic pool of Aβ 
(55). In the AD mouse model, we could observe similar effects. 
Deleting Lrp1 in brain endothelium severely increased soluble 
Aβ levels and elevated the Aβ1–42/Aβ1–40 ratio. This led to severe 
effects on cognitive function, supporting the idea that soluble Aβ, 
but not plaque-bound Aβ, correlates with AD-related symptoms.
It has been shown that LRP1 is required for APP trafficking 
and Aβ production. Inhibition of LRP1 in cultured cells has been 
shown to significant reduce Aβ production (57). In the 5xFAD 
model, these findings contradict the soluble Aβ accumulation 
that we observed in 5xFAD Lrp1BE–/– mice. However, much of the 
Aβ in the brain is produced by neurons in which there is both high 
APP and LRP1 expression. LRP1 expression in neurons is not 
affected in this mouse model. The knockout of Lrp1 is restricted 
to brain endothelium and choroid plexus epithelium. As endo-
thelial cells constitute only 1% to 2% of all cells in the brain (58), 
we do not believe that in 5xFAD Lrp1BE–/– mice there is a signifi-
cant effect on APP trafficking and overall Aβ production in the 
brain, compared with that in 5xFAD Lrp1BEfl/fl mice. Additionally, 
the results taken from the Aβ in vivo injection experiments in 
Lrp1BE–/– mice are mirrored by these from the 5xFAD mice crossed 
into the Lrp1BE–/– background. Therefore, we assume that the role 
of Aβ production in this paradigm is minimal.
In conclusion, the data gathered with the brain endothelial–spe-
cific Lrp1 knockout mouse model prove that LRP1 in brain vascula-
ture plays a key role in regulating brain Aβ levels. Although there are 
additional methods of Aβ clearance (6, 7, 38, 39), our and other data 
Figure 6. Brain endothelial LRP1 substantially mediates Aβ clearance in vivo. (A) 5.14 nM [125I] Aβ1–42 and 40 μCi/ml [14C]-inulin, a paracellular marker, were 
microinfused into brain ISF of the caudate nucleus. Efflux was studied at designated time points by determining remaining radioactivity in the brain (n = 5, 
n = 5, n = 3, n = 3, n = 4, n = 5 mice per group from left to right). (B) No alteration was observed in the bulk flow clearance of [14C]-inulin (n = 5 mice per group). 
(C) Efflux across the BBB of 5.14 nM [125I] Aβ1–42 15 minutes after microinfusion in brain ISF demonstrated the substantial contribution of LRP1 (n = 5 mice 
per group). (D and E) Scarce presence of tracers in CSF 15 minutes after microinjection into the caudate nucleus (n = 3 mice per group). (F) Contribution of 
brain endothelial LRP1 to total and BBB clearance of 5.14 nM [125I] Aβ1–42 within 15 minutes (n = 5 mice per group). Data represent mean ± SEM. For statistical 
analyses, unpaired t test was used. *P < 0.05, **P < 0.01.
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Methods
Additional details are available in the Supplemental Methods.
Animals. Inducible Lrp1 brain endothelial–specific knockout 
mice (Lrp1BE–/–) were generated by breeding Lrp1fl/fl mice (25) with 
Slco1c1-CreERT2 mice (24). To study Aβ transport without exter-
nal invasion in vivo, we crossed Lrp1BE–/– mice with 5xFAD mice, a 
show that vascular transport across the BBB is of crucial importance 
for rapid Aβ elimination from brain (8, 11, 15). Recent reports have 
identified different targets and strategies to restore and promote Aβ 
clearance at the BBB (16, 33, 59). As LRP1 levels decrease with aging 
and in AD, maintaining the function of Aβ transporters could be a 
potential strategy for treatment and prevention of AD.
Figure 7. BBB clearance of Aβ species in 5xFAD mice is regulated by brain endothelial LRP1. Representative immunoprecipitations of (A) plasma Aβ, (B) 
soluble brain Aβ, and (C) insoluble brain Aβ, with 6E10 antibody from 7-month-old female mice show impaired brain-to-blood clearance of Aβ1–40 and Aβ1–42. 
Quantification of (D) plasma Aβ1–40, (E) plasma Aβ1–42, (F) soluble brain Aβ1–40, (G) soluble brain Aβ1–42, (H) insoluble brain Aβ1–40, and (I) insoluble brain Aβ1–42. 
n = 3 (D and E); n = 4 (F and G); n = 5 (fl/fl) and n = 3 (–/–) (H and I). (J and K) No effect on plaque deposition in hippocampus. n = 5 (fl/fl) and  
n = 7 (–/–) (K). Quantification of Aβx–40 and Aβx–42 using ELISA showed (L) insoluble and (M) significantly elevated soluble Aβx–40 and Aβx–42 levels in 
7-month-old 5xFAD Lrp1BE
–/– mice. n = 12, n = 5, n = 12, n = 5 (L) and n = 10, n = 5, n = 12, n = 5 (M) from left to right. Data represent mean ± SEM of n = 5. All 
samples except for those shown in lanes 1 and 2 in C were analyzed on the same Western blot but rearranged for clearer presentation. A shorter exposure 
is shown for Aβ1–40 and Aβ1–42 standards in A. For statistical analyses, unpaired t test was used. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar: 200 μm.
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bovine serum (First Link), 100 U/ml penicillin (Gibco), 100 μg/ml 
streptomycin (Gibco), 2 mM l-glutamine (Gibco), 4 μg/ml puromycin 
(Alexis), and 1 ng/ml FGF (R&D Systems) at 37°C and 5% CO2. Cells 
were cultured in the cellZscope device, in which transendothelial elec-
trical resistance (TEER) and capacitance were monitored over time. 
Puromycin was withdrawn after 4 days in culture. When cells reached 
confluency and the capacitance was around 1 μF/cm2, culture medium 
was removed and serum-free DMEM/Ham’s F12 (Gibco) medium 
containing 1 mM l-glutamine, 100 U/ml penicillin, and 100 μg/ml 
streptomycin was added. 550 nM hydrocortisone (Sigma-Aldrich) was 
supplemented to induce high TEER. The following day transport stud-
ies were performed.
Lysis of brain endothelial cells. For Western blot analysis, isolated 
primary cortical brain endothelial cells were solubilized in lysis buffer 
(50 mM TrisOH, 150 mM NaCl, 0.02% [w/v] NaN3, 1% [v/v] Nonidet 
P-40 supplemented with a cocktail of phosphatase and proteinase 
inhibitors [PhosStop, Complete, Roche Applied Science]). Homoge-
nates were centrifuged for 20 minutes at 15,000 g, and the superna-
tant was collected.
Analysis of recombination on DNA level. To analyze the efficiency 
of the tamoxifen-induced gene excision on DNA level, PCR analysis 
was performed using a PCR strategy with 3 primers to simultaneously 
detect WT, loxP flanked, and deleted Lrp1 alleles (26). Genomic DNA 
was extracted from isolated primary cortical brain endothelial cells 
with the GenElute Mammalian Genomic DNA Miniprep Kit (Sig-
ma-Aldrich) according to the manufacture’s protocol. Three primers 
(A, 5′-TGGGATGAGGTAGACGCAGT-3′; B, 5′-CCTGGAGAAC-
GTTCCAGTTC-3′; C, 5′-CCTGGAGAACGTTCCAGTTC-3′) were 
simultaneously used in one PCR reaction to investigate the efficiency 
well-established AD model that harbors 3 APP mutations and 2 prese-
nilin 1 mutations that are linked to FAD. Primers for genotyping are 
as follows: Lrp1-fwd, 5′-CATACCCTCTTCAAACCCCTTCCTG-3′ 
and Lrp1-rev, 5′-GCAAGCTCTCCTGCTCAGACCTGGA-3′ for 
loxP, Cre-fwd, 5′-GCTATTCATGTCTTGGAAGCC-3′ and Cre-rev, 
5′-CAGGTTCTTCCTGACTTCATC-3′ for Cre; and 5xFAD-fwd 
5′-CATGACCTGGGACATTCTC-3′ and 5xFAD-rev 5′-GTAGCAGAG-
GAGGAAGAAGTG-3′ for the 5xFAD site. Mice were housed on a 
12-hour-light cycle. Unless stated otherwise, the animals had ad libi-
tum access to water and a standard laboratory diet. In all experiments, 
littermates harboring (Lrp1BE–/–) or lacking (Lrp1BEfl/fl) the Cre allele were 
used. In order to induce recombination, 4- to 11-week-old mice were 
injected i.p. with 2 mg tamoxifen (T5648, Sigma-Aldrich) for 5 to 7 
consecutive days. The analysis of recombination was examined 3 days 
after the last treatment. Lrp1BEfl/fl control animals were treated equally. 
To maintain Cre-mediated recombination over time, 7-month-old ani-
mals were fed chow supplemented with 400 mg tamoxifen citrate per 
kilogram dry weight (CRE Active TAM400, LASvendi).
Reagents and antibodies. [125I] Aβ1–42 was purchased from Phoe-
nix Peptide, and [14C]-inulin was purchased from PerkinElmer. For a 
detailed description of all primary and secondary antibodies, see Sup-
plemental Table 1.
Isolation of primary mouse brain capillary endothelial cells. Pri-
mary mouse brain capillary endothelial cells were isolated from 
8- to 12-week-old littermate mice according to a standard protocol 
as described previously (32, 34). Cells were plated on 24-well Tran-
swell filters (pore size, 0.4 μm; surface area, 33.6 mm2; Greiner Bio-
One) coated with collagen IV/fibronectin (Sigma-Aldrich). Cultures 
were maintained in DMEM supplemented with 20% plasma-derived 
Figure 8. No difference in 
astrogliosis and microgliosis due 
to brain endothelial knockout 
of LRP1 in 5xFAD mice. Immu-
noreactivity for (A and B) Iba1 
(microgliosis) and (C and D) GFAP 
(astrogliosis) in hippocampi of 
5xFAD Lrp1BE
–/– (n = 5) and 5xFAD 
Lrp1BE
fl/fl (n = 7) mice (mean ± 
SEM). Representative results are 
shown in A and C. For statistical 
analyses, unpaired t test was 
used. Scale bar: 200 μm.
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10 μg/ml Na-fluorescein in 1:1 Tris-HCl/methanol (v/v) were added 
to each plate. The intensity of fluorescence was read at λ = 519 nm 
(excitation, 488 nm).
In vitro transcytosis of [125I] Aβ1–42. In order to study Aβ transcytosis 
in vitro, a standard transport model was used (5, 32, 34). [125I] Aβ1–42 
(0.05 nM to 5 nM) and 1 μCi/ml [14C]-inulin, a marker for paracellu-
lar diffusion, were added to serum-free media supplemented with 
550 nM hydrocortisone and 40 mM HEPES and incubated at 37°C. 
To study blood-to-brain transport, 10 and 60 μl samples were taken 
from the luminal compartment after 45 minutes (0.1–5 nM [125I] Aβ1–42) 
or 90 minutes (0.05 nM [125I] Aβ1–42). The longer time period for the 
0.05 nM [125I] Aβ1–42 concentration was necessary to be able to detect 
the amounts of transported protein. To investigate the amount of 
intact [125I] Aβ1–42 transported to the luminal side, 60 μl 15% TCA was 
added to a 60 μl luminal media sample and incubated for 10 minutes 
at 4°C. Samples were then centrifuged at 10,000 g for 10 minutes. 
Pellets (representing intact [125I] Aβ1–42) were counted for [125I]. Trans-
port of intact [125I] Aβ1–42 across the monolayer was calculated as Aβ1–40 
transcytosis quotient (TQ) using the following formula: Aβ1−42 TQ = 
([125I] − Aβ1−42 luminal/[125I] − Aβ1−42 input)/([14C] − inulin acceptor/
[14C] − inulin input). Probes were counted on a Wallac Wizard2 2470 
automatic γ-counter (PerkinElmer) for [125I] or on a Tri-Carb 2800 TR 
Liquid Scintillation Analyser (PerkinElmer) for [14C].
Brain efflux index method. A standard method was used to quan-
tify brain-to-blood efflux rates (8, 11, 61). A stainless steel cannula was 
stereotaxically implanted into the right caudate putamen of age- and 
sex-matched mice that had been anesthetized with ketamine (800 
mg/kg) and medetomidine (5 mg/kg). The cannula tip coordinates 
were as follows: 0.9 mm anterior from bregma, 1.9 mm lateral from 
midline, and 2.9 mm below the surface. Before injection of tracer mol-
ecules, animals recovered for 4 to 6 hours, a time point that precedes 
the start of the substantial inflammatory process, as assessed by his-
tological analysis of tissue (negative staining for reactive astrocytes 
[GFAP] and reactive microglia [antiphosphotyrosine]), but allows 
partial BBB repair for large molecules, as reported previously (15, 61). 
0.5 μl tracer fluid containing 1 μCi/ml [14C]-inulin (reference marker) 
and physiological amounts of [125I] Aβ1–42 (5.14 nM) was injected with a 
26-gauge needle attached to an UltraMicroPump controller (UMP3-1, 
Word Precision Instruments) into ISF over 5 minutes. After injection, 
the microsyringe was left in place for 5 minutes. Blinded brain samples 
were collected at different time points and prepared for analysis.
CSF isolation. 15 minutes after injection of tracers, as described 
above, 3.5- to 12-μl samples of CSF were taken from animals via cis-
terna magna puncture, as reported elsewhere (62), and used for radio-
active analysis.
Calculation of in vivo [125I] Aβ1–42 clearance. In vivo [125I] Aβ1–42 clear-
ance was calculated as reported before (8, 11, 15). The percentage 
of radioactivity remaining in the brain was calculated as follows: % 
recovery in brain = 100 × (Nb/Ni), where Nb is the radioactivity in the 
brain at the end of the experiment and Ni is the radioactivity injected 
into the brain, as illustrated by [14C]-inulin (measured in dpm) and 
TCA-precipitable [125I]-radioactivity (measured in cpm). The clear-
ance rate for inulin, kinulin, provides a measure of ISF flow, as inulin is 
neither transported across the BBB, nor retained in the brain (8). It is 
calculated as follows: Nb(inulin)/Ni(inulin)= e–kinulin × t.
As previously reported, there are two major methods of Aβ elimi-
nation: direct transport across the BBB into the bloodstream and bulk 
of the Cre-mediated recombination with regard to to the length of the 
different amplified products. Primers were designed to amplify a 541-
bp product for the unexcised allele containing the loxP site, a 507-bp 
product for the WT allele, and a 325-bp product for the excised allele 
after Cre recombinase–catalyzed recombination.
Capillary depletion. Capillary-depleted brain homogenates were 
prepared as described elsewhere, using dextran density gradient cen-
trifugation to separate microvessels from total brain homogenates (60).
Brain IgG extravasation. Levels of IgG in brains of Lrp1BE–/– mice 
and controls at 36 weeks of age were evaluated by Western blotting. 
The mice were anesthetized with 125 mg/g pentobarbital and per-
fused transcardially with ice-cold PBS (137 mM NaCl, 2.7 mM KCl, 8.1 
mM Na2HPO4 • 2H2O, 1.76 mM KH2PO4, pH 7.4). Brains were homog-
enized in lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM 
Na2EDTA, 1 mM EGTA, 1% [v/v] Triton, 2.5 mM sodium pyrophos-
phate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin, 1 
mM phenylmethanesulfonylfluoride) on ice. The protein extracts were 
separated by SDS-PAGE, transferred onto nitrocellulose membranes 
(Amersham Hybond ECL), and then blocked in 5% (w/v) skim milk in 
TBST (20 mM Tris, 137 mM NaCl, 0.1% [v/v] Tween-20).
Brain fluorescein extravasation. BBB permeability was assessed 
with fluorescein extravasation in brains of Lrp1BE–/– mice and con-
trols at 36 weeks of age. The experiment was performed by admin-
istering mice 1.2 mg Na-fluorescein (Sigma-Aldrich) via retro- 
orbital intravenous injection under isoflurane anesthesia (5% in 
70% N2/30% 02). After 30 minutes, mice were anesthetized with 
pentobarbital 125 mg/g (w/w) and perfused transcardially with 
ice-cold PBS (137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4 • 2H2O, 
1.76 mM KH2PO4, pH 7.4) containing 10 IU/ml heparin. Brains were 
homogenized in 50 mM Tris-HCl, pH 8.0, and centrifuged at 16.1 g 
for 30 minutes. Supernatants were transferred to new tubes, and an 
equal volume absolute methanol was added. Samples were centri-
fuged at 16.1 g for 30 minutes, and the supernatant was transferred 
to a 96-well assay plate. A series of standards containing 0.001 to 
Figure 9. Preferential clearance of Aβ1–40 species by brain endothelial 
LRP1. Contrasting the Aβ1–42/Aβ1–40 ratio in 5xFAD Lrp1BE–/– and 5xFAD 
Lrp1BE
fl/fl Aβ pools demonstrates a differential clearance of Aβ species. 
Densitometry analysis of immunoprecipitated soluble brain Aβ, insolu-
ble brain Aβ, and plasma Aβ with 6E10 antibody from 7-month-old mice 
(n = 3, n = 5, n = 7, n = 6, n = 3, n = 3 from left to right) showed higher 
Aβ1–40 and Aβ1–42/Aβ1–40 ratios in plasma and lower and Aβ1–42/Aβ1–40 ratios 
in brain fractions when LRP1 is present in brain endothelial cells. Data 
represent mean ± SEM. For statistical analyses, unpaired t test was 
used. *P < 0.05, **P < 0.01, ***P < 0.001.
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centrifuged at 55,000 g for 20 minutes at 4°C. Supernatants, containing 
insoluble plaque-associated Aβ, were immediately frozen at –80°C.
The levels of Aβx–40 and Aβx–42 peptides in brain extractions were 
blindly determined using a cell-based sandwich ELISA assay as 
described previously (63).
Immunoprecipitation of Aβ. Total Aβ was immunoprecipitated 
from blinded samples of blood serum and soluble and insoluble brain 
pools by mixing 5-fold concentrated detergent buffer (50 mM HEPES 
[pH 7.4], 150 mM NaCl, 0.5 % [v/v] Nonidet P-40, 0.05% [w/v] SDS 
and protease inhibitor cocktail [Roche Applied Science]) with the 
respective samples. Magnetic Dynabeads (M-280 Sheep Anti-Mouse 
IgG, 11201D, Novex) containing sheep anti-mouse IgG attached to 
their surface were precoated with 6E10 antibody (Covance) according 
to the manufacturer’s protocols and added to the samples. After over-
night incubation at 4°C, samples were washed 3 times in PBS, 0.1% 
(w/v) BSA, and once in 10 mM Tris-HCl, pH 7.5. After heating the sam-
ples to 95°C in 25-μl sample buffer (0.36 M Bis-Tris, 0.16 M bicine, 1% 
[w/v] SDS, 15% [w/v] sucrose, and 0.0075% [w/v] bromphenol blue) 
the supernatants were subjected to PAGE.
flow clearance. In addition, Aβ can be retained in the brain by binding 
to transport proteins or cell-surface receptors (8).
According to our model, the fraction of Aβ remaining in the brain 
can be expressed as follows: Nb(Aβ)/Ni(Aβ) = (a1 + a2) × e–(k1+k2) × t, where 
a1= k2/(k1+k2), a2= (1 – (k2/(k1 + k2))), k1 signifies the total efflux, and k2 
represents the retention in the brain.
Clearance of [125I] Aβ1–42 via the BBB was calculated as [(1 – 
Nb(Aβ)/Nb(Aβ) – (1 – Nb(inulin)/Nb(inulin))] × 100 using a standard time of 
15 minutes where efflux was linear. Clearance of brain endothelial 
LRP1 was calculated by subtracting BBB-mediated clearance of 
Lrp1BE–/– mice from Lrp1BEfl/fl mice.
Measurement of Aβ species by ELISA. Brains were weighed and sub-
jected to a sequential Aβ extraction. Then, brains were homogenized in 
PBS containing complete protease and phosphatase inhibitor (Roche 
Applied Science) using a glass homogenizer and subsequently centri-
fuged at 55,000 g for 20 minutes at 4°C. The supernatant, containing 
soluble brain Aβ, was removed and stored at –80°C. Then, the pellet was 
dissolved in 2% SDS in PBS containing complete protease and phos-
phatase inhibitor, sonificated, incubated for 30 minutes on ice, and 
Figure 10. Deletion of Lrp1 in brain endothelial cells leads to cognitive deficits in 5xFAD Lrp1BE–/– mice. 7-month-old female 5xFAD Lrp1BE–/– (n = 5), 5xFAD 
Lrp1BE
fl/fl (n = 7), Lrp1BE
–/– (n = 5), and WT (n = 6) control mice were tested. (A) Animals underwent acquisition training to learn to use proximal and distal 
cues to navigate a path to a hidden platform. A significant difference in the escape latency of 5xFAD Lrp1BE
–/– mice compared with that of all other groups 
was seen on days 3 to 5. (B and E) Swimming speed was not affected in all mice tested. (C) Spatial reference memory deficits in 5xFAD Lrp1BE–/– mice were 
shown in the probe trial, in which 5xFAD Lrp1BE
–/– mice spent significantly less time in the target quadrant than all other groups of mice. The probe trial was 
given after the acquisition training phase to assess spatial reference memory. (D) 5xFAD Lrp1BEfl/fl mice showed no impairment of spatial reference memory, 
as reflected by the significant greater percentage of time spent in the target quadrant (P < 0.001 target vs. left, right, and opposite quadrant). The probe 
trial revealed a significant impairment of spatial reference memory in 5xFAD Lrp1BE
–/– mice, as they showed no preference for the target quadrant. T, target 
quadrant; L, left quadrant; R, right quadrant; O, opposite quadrant. Data represent mean ± SEM. For statistical analyses, the following test was used: 
repeated-measures ANOVA followed by Bonferroni multiple comparisons. *P < 0.05, ***P < 0.001.
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The experiment began with 3 days of cued training, during which 
the platform was marked with a triangular flag. Both the location of 
the platform and the position from where the mice were introduced 
into the pool changed between trials. Each mouse received 4 training 
trials per day with an average intertrial interval of 15 minutes.
24 hours after the last day of cued training, mice performed 5 
days of acquisition training. For this the flag was removed from the 
platform. In addition to distal cues existing in the room, proximal 
cues were attached to the outside of the pool. The platform position 
remained stationary for each mouse throughout training. Trials were 
conducted as they were during the cued training phase.
24 hours after the last acquisition trial, a probe test was performed 
to analyze spatial reference memory. The platform was removed, and 
mice were introduced into the water from a novel entry point. Mice 
were allowed to swim freely for 1 minute while their swimming path 
was recorded. After the probe trial, mice were sacrificed.
Statistics. Statistical analysis was performed using GraphPad 
Prism software (version 5, GraphPad Software). Unpaired 2-tailed t 
tests and 1-way ANOVA followed by Bonferroni multiple comparisons 
were used. Statistical significance was defined as P < 0.05.
Study approval. All animal studies were conducted in compliance 
with European and German guidelines for the care and use of labora-
tory animals and were approved by the Central Animal Facility of the 
University of Mainz and the ethical committee on animal care and use 
of Rhineland-Palatinate, Germany.
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Aβ separation with 8 M urea SDS gel and Western blotting. Separa-
tion of immunoprecipitated Aβ peptides was performed together with 
peptide standards on 0.75-mm 10% T/5% C polyacrylamide 8 M urea 
SDS gels. For separation of Aβ1–40 from Aβ1–42, a final concentration of 
0.3 M H2SO4 was used in resolving gels. Peptides were transferred 
to an Immobilion-P PVDF membrane via semi-dry Western blotting 
(Bio-Rad) at 46 mA for 45 minutes. Membranes were boiled for 3 min-
utes in PBS and blocked in 5% skim milk in TBST (20 mM Tris, 137 
mM NaCl, 0.1% [v/v] Tween-20) for 30 minutes afterward.
Immunohistochemistry and immunocytochemistry. 8-μm frozen 
sections of perfused mouse brains or isolated cells were fixed in 
ice-cold methanol for 30 minutes. Unspecific binding sites were 
blocked using a solution of 10% (v/v) goat serum and 1% (w/v) 
BSA in PBS. Unconjugated chicken anti-mouse IgG (SAB3701114, 
Sigma-Aldrich) was used to block endogenous mouse IgG. Sec-
tions were incubated in primary antibody solution at 37°C for 1 
hour, washed, and incubated at room temperature with secondary 
antibodies for 90 minutes. For some experiments, cell nuclei were 
stained with DRAQ5 (Biostatus Limited) in PBS for 10 minutes at 
room temperature. Samples were embedded in Prolong Gold Antif-
ade Reagent (Invitrogen), dried overnight at room temperature, and 
analyzed with a confocal laser scanning microscope. Stainings were 
documented with a LSM710 microscope (Zeiss) equipped with ZEN 
2011 SP2 software.
Paraffin sections were stained as described previously (64). 
Images were obtained using an Olympus BX-51 microscope equipped 
with a DP-50 camera (Olympus).
Quantification of plaque load, astrogliosis, and microgliosis. Plaque 
load quantification was performed as described previously (65). For 
quantification of astrogliosis and microgliosis, sections were stained 
with anti-GFAP and anti-IBA1 and analyzed likewise. Three sections 
per animal were analyzed.
Chemiluminescence detection. Signal detection in all Western blot-
ting experiments was carried out using HRP-conjugated secondary 
antibodies and ELC assay solutions (Millipore and Thermo Scientific 
Pierce) and LAS-3000 mini (Fujifilm). Western blots signals were 
quantified using NIH ImageJ (version 1.44).
Generation of monoclonal 11E2 anti-LRP1. Monoclonal 11E2 was 
generated as described previously (66). Briefly, Prnp knockout mice 
were immunized with purified LRP1 ligand–binding domains II and 
IV, and a fusion to generate hybridoma was performed according to 
standard protocols (66). Screening of hybridoma supernatants was 
done using dot blot and Western blot to detect the immunogen.
Spatial learning and spatial reference memory assessed by Morris 
water maze. The ability of vision of the mice was tested by visual plac-
ing (42) before mice entered the Morris water maze. Spatial reference 
memory in 5xFAD Lrp1BE–/– mice and 5xFAD Lrp1BEfl/fl control mice 
was assessed using the Morris water maze (40) by a blinded inves-
tigator as described previously (41). In brief, mice learn to locate a 
hidden platform in a circular pool filled with opaque water. The pool 
was divided into 4 virtual quadrants that were defined based on their 
spatial relationship to the platform: left, right, opposite, and target 
quadrant, which contained the goal platform. ANY-Maze video-track-
ing software (Stoelting Co.) was used to record escape latency, swim-
ming speed, and quadrant preference. 7-month-old female 5xFAD 
Lrp1BE–/– (n = 7), 5xFAD Lrp1BEfl/fl (n = 7), Lrp1BE–/– (n = 5), and WT (n = 6) 
control mice were tested.
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